# GloriousMed Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gloriousmed-technology-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.gloriagene.cn
- Total disclosed funding: $27M
- Latest round: Series B (Nov 8, 2021)
- Investors on record: 3

## About

Established in 2015 and based in Beijing, China, GloriousMed Technology Co., Ltd. is a comprehensive big data medical platform specializing in the integration of tumor precision immunodiagnosis and treatment, which integrates production, education and research. The company build a industry-university-research service system to provide a complete set of solutions for the integration of tumor precision immunodiagnosis and treatment, including  the Chinese Academy of Sciences, Chinese Academy of Medical Sciences. The company has a testing institution with 2,000 square meters that the scope of testing and diagnosis projects carried out includes medical laboratory, clinical body fluids, hematology, clinical chemistry, clinical immunization, serology, cell and molecular biology, etc. In 2017, it proposes the "Tumor Immunity Ark Project", which combines clinical phenotype data and drug efficacy follow-up data, explore the evaluation standards and evaluation system of tumor immunodiagnosis and treatment, and finally realize clinical transformation.

The company provides integrated solution for precision diagnosis and treatment of tumors, relying on genetic testing technology and multi-dimensional and multi-omics testing platform. Specific solution includes urinary tumors, breast cancer, lung cancer, other solid tumors, and precision immunity.

The company plans to build an academic communication platform for clinical experts, pharmaceutical companies, and basic research experts. As well as it will promote the application and registration of standard test kits for products tested in clinical research and application.

## Funding rounds

- Series B, Nov 8, 2021, $16M — Hangzhou Fuzhuo Venture Capital
- Series A, Aug 1, 2018, $11M — 6 Dimensions Capital, Shiyu Capital

## Investors

- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series A
- Shiyu Capital (https://capitalatlas.ai/funds/shiyu-capital) — Series A
- Hangzhou Fuzhuo Venture Capital (https://capitalatlas.ai/funds/hangzhou-fuzhuo-venture-capital) — Series B